Frazier Life Sciences Viii, L.P. has bought stock on 3 days since Sep 2018

Frazier Life Sciences VIII, L.P. is a venture capital investment fund and corporate insider affiliated with Frazier Healthcare Partners, a long‑standing healthcare-focused private equity and venture capital firm founded in 1991.( As a limited partnership, it is treated as a company/firm rather than an individual insider. The fund closed with more than $260 million in capital commitments and was established as Frazier’s first sector-specific life sciences fund, dedicated exclusively to investing in companies developing novel therapeutics.( Through this vehicle, Frazier has held significant positions in biopharmaceutical companies such as Alpine Immune Sciences, Inc. (ALPN), where it has reported ownership of approximately 10% and related insider trading activity in SEC filings.(

Frazier Life Sciences VIII, L.P. operates within the broader Frazier Life Sciences platform, which manages venture capital and public equity strategies focused on advancing innovative biopharmaceuticals that address important unmet medical needs.( Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize novel therapeutics, building product-focused companies capable of generating meaningful clinical data and successfully commercializing therapies for patients.( The life sciences team is headquartered in Palo Alto, California, with additional offices in San Diego, Boston, and Seattle, and is led by senior investment professionals of Frazier Life Sciences and Frazier Healthcare Partners, though the fund itself—Frazier Life Sciences VIII, L.P.—serves as an investment vehicle rather than an operating company with its own distinct executive suite.(

Written by Perplexity from public sources.